Finance and Economics APP learned that recently, the 2023 Guangdong Science and Technology Award was announced. Nominated by the Guangzhou Science and Technology Bureau, the First Affiliated Hospital of Guangzhou Medical University and Guangzhou Benchmark Medical Co., Ltd. jointly developed the technology advancement award-winning smart technology-based Pulmonary Nodule/Lung Cancer Early Screening-Diagnosis-Treatment System.

The key to reducing the high mortality rate of lung cancer is to increase the screening rate of early lung cancer, improve the accuracy of lung cancer surgery, and reduce the risk of postoperative recurrence. The award-winning project team developed an innovative early screening-diagnosis-treatment system for Pulmonary Nodule/Lung Cancer based on intelligent technology. This includes establishing a real-world multidimensional big data database for lung cancer: creating multi-omics data for a population of 0.12 million, a multimodal database of 0.6 million CT data, a big data platform focusing on lung cancer/pulmonary nodules, and a database of over ten thousand thoracoscopic surgery videos, laying the methodological foundation for subsequent multi-center AI data model training and application.

The project also includes the development of an artificial intelligence lung cancer diagnostic model by Benchmark Medical: the world's first combined diagnostic system PulmoSeek Plus (liquid biopsy + CT imaging AI) for lung cancer. This product is Benchmark Medical's core product, leading the early screening and diagnosis of lung cancer, and can be used for the differential diagnosis of benign and malignant lung nodules, follow-up management, and preoperative prediction of high-risk nodules' invasion degree of lung adenocarcinoma, especially suitable for 5-30mm lung nodules, with advanced, non-invasive, accurate characteristics. The early diagnosis accuracy is >91%, sensitivity is >98%, can reduce unnecessary examinations/surgeries by 85%, and avoid delays in treatment of 72% of malignant nodules.

Earlier this year, Benchmark Medical's another DNA methylation diagnostic product, UriFind, won the 2024 National Science and Technology Progress Second Prize. This product assists in the diagnosis of suspected urinary epithelial cancer patients and postoperative follow-up of urinary epithelial cancer patients by detecting urine cell DNA methylation. It has significant advantages in the diagnosis of early, small, residual, and recurrent tumors, requiring only 100mL of random urine to detect bladder cancer, renal pelvic cancer, ureteral cancer, with non-invasive, painless, convenient, and comprehensive features, and its performance is comparable to the clinical gold standard (cystoscopy + histological biopsy). This product is also a First-in-Class product, has obtained breakthrough medical device certification (BTD) from the FDA in the United States, commercialized LDT in the United States, and obtained a Class III medical device registration certificate from the National Medical Products Administration (NMPA) earlier this year.

Kingmed Global (09960) announced in September of this year its acquisition plan for 100% equity of Guangzhou Benchmark Medical Co., Ltd., and the project is currently in progress. Dr. Jianbing Fan, the founder of Benchmark Medical, has also joined the group as Chief Scientific Officer of Kingmed Global to lead R&D innovation in specific technical areas of the company and provide decision-making support and consulting services. Looking ahead, Kingmed Global will capitalize on Benchmark Medical's advanced technology and scientific patents to more rapidly enter the field of major solid tumor detection such as lung cancer and gastric cancer, achieve strong alliances of resources, further enhance the group's market competitiveness and comprehensive influence in the industry.